54 results about "Flu immunization" patented technology

The invention provides an influenza vaccine adjuvant based on lentinan as well as a preparation method and application thereof. The active ingredient of the vaccine adjuvant is lentinan, the lentinan is extracted from fresh lentinus edodes through a water extraction and alcohol precipitation method, no additional chemical modification is needed, the vaccine adjuvant can be used for preparing the influenza virus vaccine, and the influenza virus vaccine at least contains one of three inactivated influenza virus antigens, namely H1N1 A, H3N2 A and Victoria B. The invention also provides a vaccine preparation and a preparation method thereof, the vaccine preparation comprises the vaccine adjuvant and an influenza virus vaccine, the content of lentinan in the vaccine preparation is 4 mg / mL, and the vaccine preparation has an immunological enhancement effect.

The invention relates to the technical field of biology, in particular to an MDCK cell strain and application of the MDCK cell strain in preparation of influenza vaccines. The invention provides an MDCK cell strain, the preservation number of which is CCTCC NO: C202504. The cell strain not only can maintain high sensitivity and high yield to influenza viruses and ensure the yield and quality of vaccines, but also can remarkably improve the biological safety of cell matrix influenza vaccines due to elimination of tumorigenicity risk, and has a good application prospect. And a key technical support is provided for promoting domestic research and development and marketing of influenza vaccines based on cell culture.

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.

Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

This invention provides a data-driven method and system for optimizing influenza vaccine transport, relating to the fields of data processing and intelligent optimization. The method includes acquiring multi-source dynamic data corresponding to the influenza vaccine transport task, and performing time alignment and feature construction on the multi-source dynamic data to obtain feature vectors representing a set of candidate transport links and a set of candidate transport nodes. The candidate transport links represent the transport modes and path combinations from the starting node to the destination node. This data-driven method and system for optimizing influenza vaccine transport establishes a data-driven machine learning prediction model by performing time alignment and feature construction on multi-source dynamic data such as road traffic, weather, transport node operational capabilities, and cold chain status. This model jointly predicts transport time, node waiting time, and temperature exceedance risks, achieving accurate characterization of the timeliness and cold chain risks in the influenza vaccine transport process.

The invention belongs to the technical field of biological medicines, and particularly relates to a dissociation liquid applied to an aluminum adjuvant adsorption influenza vaccine and a method for measuring the antigen content. The dissociation liquid disclosed by the invention is prepared from a potassium phosphate salt solution, diethanol amine, TritonX-100, tween-20, dodecyl dimethyl betaine and water. The dissociation liquid is excellent in dissociation efficiency, the dissociation recovery rate of the dissociation liquid to H1N1, H3N2 and BV type influenza vaccine hemagglutinin reaches 106%-110%, the antigen activity can be effectively protected, operation is easy and convenient, adaptability is wide, a dissociated sample can be directly used for mainstream detection methods such as a one-way immunodiffusion test, an enzyme-linked immunosorbent assay and a high performance liquid chromatography method, and the dissociation liquid has good application prospects. The precise quantification of the antigen content in the aluminum adjuvant adsorption influenza vaccine is realized, and a reliable technical support is provided for vaccine quality control.

The present application provides vaccines comprising an inactivated influenza virus and an adjuvant comprising a triterpenoid saponin, a sterol, and an immunostimulatory oligonucleotide comprising CpG. Also provided are methods of using such vaccines.

The application belongs to the technical field of biological medicine, and particularly relates to an adjuvant influenza vaccine and a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS buffer solution; the adjuvant is prepared by using mixed oil and an auxiliary agent, the mixed oil comprises squalene, medium-chain triglyceride and alpha-tocopherol; and the auxiliary agent comprises sorbitan trioleate Span-85, Tween 80 and vitamin E succinate polyethylene glycol ester. The adjuvant influenza vaccine prepared by the application has good immunization effect, and can especially improve the overall effect of a tetravalent adjuvant influenza vaccine on four viruses.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The invention relates to the technical field of biology, and particularly provides an influenza virus live vaccine as well as a preparation method and application thereof. The invention aims to solve the problems that influenza vaccines in the prior art generally face ineffective single immunization, cellular immune deficiency, insufficient broad-spectrum protection and high safety risk. Therefore, the invention provides an influenza virus live vaccine which comprises influenza virus which is not subjected to attenuation treatment. The influenza virus live vaccine disclosed by the invention breaks through the safety limitation of the traditional attenuated live vaccine, the fact that an unattenuated influenza epidemic strain (such as an H1N1 PR8 strain) can realize safe and efficient immune response through subcutaneous inoculation is proved for the first time, and a brand new technical path is provided for the development of influenza vaccines.

Disclosed herein are mosaic avian influenza (e.g., H5N1) proteins or fragments thereof. Also disclosed herein are nucleic acid constructs, avian influenza vaccine vectors, avian influenza vaccines, host cells, pharmaceutical compositions, and kits comprising the mosaic avian influenza (e.g., H5N1) proteins or fragments thereof. Also disclosed herein are methods of eliciting an immune response in a subject and methods of preventing, reducing the incidence of, attenuating, or treating avian influenza infection in a subject in need thereof.

Provided are an influenza vaccine as a nasal spray, and a preparation method therefor and the use thereof. In the vaccine, a fusion protein contains an influenza virus strain HA protein or a fragment thereof, an influenza virus protein epitope and ferritin; and an adjuvant is a CpG1009 adjuvant for enhancing humoral immunity and cellular immunity. The vaccine composed of the fusion protein and the new CpG adjuvant can induce a strong protective effect against challenge.

The present invention provides new canine Influenza H3N2 vaccines, including multivalent vaccines. The present invention provides an alphavirus RNA replicon particle that encodes a Canine Influenza (CIV) H3N2 hemagglutinin (HA) antigen. The present invention further provides methods of making and using the vaccines.

The present invention provides compositions comprising one or more polynucleotides that encode a neuraminidase (NA) polypeptide and a hemagglutinin (HA) polypeptide separated by a furin cleavage site and a self-cleaving 2A polypeptide. Methods of using these compositions to induce an immune response to influenza in a subject are also provided.

Provided herein are methods for making an influenza virus and / or a variant thereof, comprising: i) infecting an extra early stem cell or a cell differentiated therefrom with the influenza virus and / or the variant thereof; and ii) proliferating and isolating (such as purifying) the influenza virus and / or the variant thereof, thereby obtaining the influenza virus and / or the variant thereof. Also provided are methods for making flu vaccines and methods for evaluating and assessing agents for anti-influenza virus effects. Further provided are compounds that have anti-influenza virus effects.

A method for producing an inactivated influenza vaccine by an egg culture method according to the present disclosure includes a pathogen inactivation step for inactivating pathogens mixed into an egg other than influenza viruses.

A universal influenza mRNA vaccine is provided, the protein encoded by the universal influenza mRNA vaccine consists of the extracellular domain (M2e), hemagglutinin (HA) stem LAH region, and nucleoprotein (NP) of the influenza A virus matrix protein 2. Furthermore, the application of the universal influenza mRNA vaccine in a mouse animal model is further provided, the universal influenza mRNA vaccine can induce a robust humoral and cellular immune response, protecting mice in the animal model from infection by multiple influenza A viruses. The universal influenza mRNA vaccine is safe, effective, and has a rapid production platform.

Influenza vaccines comprising a plurality of isolated polypeptides are described, as well as influenza vaccines comprising nucleic acid encoding the aforementioned polypeptides. Polypeptides, nucleic acid molecules, vectors, cells, pharmaceutical compositions, and 5 mRNAs are described, and their use as vaccines against viruses of the influenza virus family, and methods of treatment. The vaccines comprising encoding nucleic acid comprise one or more subunits comprising the encoding nucleic acid sequence.

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNA) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, and methods of eliciting an immune response by administering the same, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) to the mRNA encoding the influenza B virus. In particular, the disclosure relates to mRNA encoding these antigens formulated into lipid nanoparticles (LNPs).

The invention provides a separated mRNA molecule. The separated mRNA molecule sequentially comprises the following elements from the 5'end to the 3 'end: (1) a 5' cap; (2) a 5 'UTR region; (3) an immunogenic fragment coding region of influenza virus hemagglutinin HA; the present invention relates to an mRNA (messenger Ribonucleic Acid) comprising (1) a 3 'UTR (Untranslated Region) region and (5) a PolyA tail, the PolyA and coding region sequences of the mRNA molecule are optimized such that the quality of the mRNA influenza vaccine is controllable and the optimal immune response is exhibited during the production of the mRNA influenza vaccine, compositions and vaccines comprising the mRNA, and methods of using the same to induce an immune response against influenza virus in a subject are also provided.

The present application relates to construction and application of H7 subtype and H5 and H7 tetravalent avian influenza DNA vaccine. The present application belongs to the field of molecular biology, and aims to provide a DNA vaccine for providing efficient immunoprotection against H7 subtype avian influenza virus. Specifically, the present application discloses a hemagglutinin protein of H7 subtype avian influenza virus, which has an amino acid sequence as shown in SEQ ID NO: 5 and / or SEQ ID NO: 6. The present application also discloses a polynucleotide encoding the protein, which has a sequence as shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. The polynucleotide can be used for preparing a vaccine against currently prevalent H7 subtype avian influenza virus. The present application also combines the vaccine with a vaccine against H5 subtype to obtain an H5+H7 tetravalent DNA vaccine, which can be used for prevention and control of current H5 subtype and H7 subtype avian influenza.

The invention discloses an influenza vaccine reagent and a preparation method thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: dissolving soybean lecithin and cholesterol in a mixed solvent of ethanol and tert-butyl alcohol to form a lipid membrane, hydrating the lipid membrane, and performing multi-step extrusion and filtration to obtain a sterile blank liposome; then encapsulating the tetravalent influenza antigen into the lipidosome; and then adding a composite freeze-drying protective additive composed of a polyvinyl alcohol grafted polysaccharide polymer and L-proline, and freeze-drying to obtain the liposome vaccine freeze-dried powder. The core of the invention is that the freeze-drying protective agent can significantly maintain the integrity of the liposome structure and the immunocompetence of the virus antigen in the freeze-drying process. The final product is quick to redissolve, has high encapsulation efficiency, excellent stability and strong immunogenicity, and is particularly suitable for constructing efficient and stable tetravalent influenza vaccines.

The present invention belongs to the technical field of biomedicine, and specifically relates to a recombinant influenza virus protein, a vaccine, and a preparation method therefor and the use thereof. To overcome the defects of existing influenza vaccines with respect to safety and high toxic side effects, a recombinant influenza virus protein is provided, which has an amino acid sequence as shown in at least one of SEQ ID No. 1 to SEQ ID No. 6. Recombinant hemagglutinin proteins of H1N1 and H3N2 subtypes, and Victoria and Yamagata lineages are expressed and purified by means of an insect baculovirus expression system, and are mixed with an adjuvant to prepare a highly immunogenic recombinant bivalent, trivalent or quadrivalent recombinant influenza virus protein vaccine. The prepared vaccine can induce high levels of specific IgG antibodies and hemagglutination-inhibiting neutralizing antibodies, the addition of adjuvant WGa01 improves the immunogenicity of the vaccine, and the provided vaccine is suitable for people allergic to eggs and has high safety.

This invention provides a method for preparing influenza virus hemagglutinin protein HA and its application, belonging to the field of biopharmaceutical technology. The method utilizes engineered cell chassis cells with glycosylation modification capabilities. After fermentation expression, the expressed protein from the engineered cells is extracted in a single step to obtain a crude extract containing the target antigen. The crude extract obtained from the engineered cells constructed in this invention, after induction, has the potential to serve as a candidate for a dual-route vaccine (intramuscular injection and mucosal immunization), providing a new technical approach for the multi-route immunization development of influenza vaccines.

The invention provides a CpG motif-containing anti-tumor deoxyoligonucleotide for interfering PD-L1 expression, which is named as ILO, and the sequence of the anti-tumor deoxyoligonucleotide is as shown in a sequence table lt; 400 gt; 1 is shown in the specification. The ILO can activate a Toll-like receptor 9 (TLR-9) and inhibit the expression of PD-L1 in tumor cells and T lymphocytes, so that the anti-tumor innate immunity and adaptive immune response of a body are enhanced at the same time. The ILO can effectively inhibit tumor growth and prolong the survival time of tumor-bearing individuals. The oligonucleotide not only can be independently used as an anti-tumor drug, but also can be combined with other anti-tumor drugs, and is suitable for treating various tumors including lung cancer and melanoma. In addition, ILO can also be used as a preparation for enhancing the efficacy of a tumor vaccine or an influenza vaccine.

The application provides a vaccine comprising an inactivated influenza virus and an adjuvant comprising a triterpenoid saponin, a sterol, and a CpG-containing immunostimulatory oligonucleotide. Methods of using such vaccines are also provided.

The present disclosure relates to compositions comprising a recombinant influenza neuraminidase tetramer comprising four copies of a fusion protein comprising a DA4B tetramerization domain, an optional linker, and an influenza NA head domain, and uses thereof. A novel linker is provided. The present disclosure also relates to a recombinant influenza neuraminidase (NA) polypeptide comprising an influenza NA head domain comprising one or more amino acid substitutions selected from the group consisting of: I99P, Y100L, T131Q, C161V, E165S, S172A, V177I, S196T, V205I, Q408M, R419V, and V453T. Also provided are compositions, methods of making, and methods of use, for example, for use as influenza vaccines.

The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more globular head domain sequences having at least 60% homology with the common stem domain sequence of H1 subtype HA (H1 HA) and / or H5 subtype HA (H5 HA), each fused with one or more globular head domain sequences having at least 60% homology with the common globular head domain sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

The invention relates to chimeric influenza vaccines. The present invention relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences fused to one or more globular head domain sequences, each of which has at least 60% homology with a stem domain common sequence of HA (H1 HA) subtype and / or H5 HA (H5 HA) subtype, the one or more globular head domain sequences each have at least 60% homology with a globular head domain common sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).